Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Long-Term Outcomes of Orbital Fat Decompression in Graves’ Orbitopathy
source: The British Journal of Ophthalmology
authors: Cheng AM, Wei YH, Tighe S, Sheha H, Liao SLsummary/abstract:
To evaluate the long-term clinical efficacy of orbital fat decompression in treating proptosis in Graves’ ophthalmopathy (GO).
Retrospective review of 1604 eyes of 845 patients with symmetric (1518 eyes) and asymmetric (86 eyes) proptosis who received orbital fat decompression between 2003 and 2014. Changes in Hertel values were evaluated at baseline, 6 months postoperatively and yearly thereafter. Recurrence of proptosis, diplopia and other complications that required additional surgeries were documented and analysed. The surgical outcome was defined as complete success if there was proptosis reduction with no recurrence and improved or no diplopia. Partial success was considered if there was proptosis reduction without recurrence yet persistent or new-onset diplopia. Failure was considered if there was recurrence of proptosis regardless of diplopia. The patient’s quality of life was also evaluated as a long-term outcome.
After follow-up for 37.9±24.4 months, 1365 eyes (85.1%) achieved complete success, 219 eyes (13.7%) achieved partial success and 20 eyes (1.2%) had failure. Newly onset diplopia and secondary decompression occurrence rate remained low at 3.3% and 0.6%, respectively. The total proptosis reduction was 4.1±1.3 mm, which was consistent all through the intermediate and long-term (5-10 years) follow-up. The amount of orbital fat removal (4.5±1.1 mL) played a significant role in the long-term Hertel change. Importantly, the overall quality of life increased significantly for GO patients after undergoing orbital fat decompression.
Orbital fat decompression has a long-term efficacy in correcting disfiguring proptosis with a low complication rate and without the need of secondary decompression procedures. This was also associated with a significant improvement in quality of life.
Hyperthyroid Patients Without Graves’ Orbitopathy are not at Increased Risk of Developing Glaucoma: A Nationwi...Purpose: Graves' disease (GD) and toxic...
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presen...Horizon Therapeutics plc today announced...
Clinical Implications of Immunoglobulin G4 to Graves’ OphthalmopathyBackground: This study aimed to explore...
Advances in Treatment of Active, Moderate-To-Severe Graves’ OphthalmopathyGraves' ophthalmopathy is defined as aut...
Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves’ Community to Focus on Thyroid Eye DiseaseFor Graves’ Disease Awareness Month in...
Relation Between Therapy for Hyperthyroidism and the Course of Graves’ OphthalmopathyBackground: The chief clinical characte...
How to Prepare for an Appointment With a TED Specialisthttps://www.youtube.com/watch?v=sKQo63E2...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.